Home › Chronic Lymphocytic Leukemia › Virginia
Chronic Lymphocytic Leukemia clinical trials in Virginia
12 studies for Chronic Lymphocytic Leukemia are looking for participants at sites in Virginia.
Cities in Virginia
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Ballad Health Cancer Care - Bristol, Bristol
- Ballad Health Cancer Care - Norton, Norton
- VCU Massey Cancer Center at Stony Point, Richmond
- and 1 more
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 12, 2026 · NCT04269902A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- University of Virginia Cancer Center ( Site 5402), Charlottesville
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Nov 6, 2026 · NCT05947851A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- USO-Virginia Oncology Associates, Hampton
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 4, 2026 · NCT06588478Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Chesapeake Regional Medical Center, Chesapeake
- Augusta Health Center for Cancer and Blood Disorders, Fishersville
- Bon Secours Memorial Regional Medical Center, Mechanicsville
- and 7 more
RecruitingObservational studyHealthy volunteers welcome
Ages 40 to 75 · All sexes · Updated Nov 4, 2026 · NCT05334069Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- VCU Massey Comprehensive Cancer Center, Richmond
- VCU Health Tappahannock Hospital, Tappahannock
RecruitingPhase 3
Ages 65 and older · All sexes · Updated Nov 3, 2026 · NCT07321652A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- University of Virginia Medical Center, Charlottesville
- Virginia Cancer Specialists, PC, Fairfax
- Oncology & Hematology Associates of Southwest VA, Norfolk
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Nov 3, 2026 · NCT07221500A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- University of Virginia Cancer Center ( Site 0040), Charlottesville
- Inova Schar Cancer Institute ( Site 0015), Fairfax
- Virginia Commonwealth University (VCU) Medical Center ( Site 0030), Richmond
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Oct 13, 2026 · NCT06136559A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- Virginia Commonwealth University Massey Cancer Center, Richmond
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Oct 5, 2026 · NCT05006716A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Blue Ridge Cancer Care (Oncology and Hematology Associates of Southwest Virginia), Roanake
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06973187Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL
- Virginia Cancer Specialists, Fairfax
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 31, 2026 · NCT07516093A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Virginia Cancer Institute, Richmond
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT05254743A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Virginia Cancer Specialists - Fairfax /ID# 268155, Fairfax
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 9, 2026 · NCT06428019From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.